STORM Therapeutics Secures $56 Million, Advances Novel Sarcoma Therapy to Phase 2
April 22, 2026, 9:32 pm
Location: United Kingdom
Employees: 11-50
Founded date: 2015
Total raised: $145.62M
STORM Therapeutics, a clinical-stage biotechnology firm, secured $56 million in Series C financing. This significant capital infusion will drive the advancement of STC-15, its groundbreaking first-in-class METTL3 inhibitor. STC-15 has now entered a pivotal Phase 2 monotherapy study targeting select sarcoma indications, with the first patient successfully dosed. This novel drug reprograms malignant cells by modulating RNA methylation. It represents a new frontier in cancer therapy. The company aims for accelerated regulatory approval. This development offers profound hope for patients facing limited treatment options for aggressive sarcomas. Investors backed this innovative approach. The biotech sector watches closely for trial results. This marks a major milestone in oncology.
STORM Therapeutics announced a major financial milestone. The company secured $56 million in Series C financing. This funding empowers critical clinical advancement. It targets a first-in-class cancer therapy. The focus is on STC-15, a novel drug candidate.
STC-15 is an oral, small-molecule inhibitor. It specifically targets METTL3. METTL3 is an RNA-modifying enzyme. This enzyme plays a crucial role in cancer development. Its inhibition offers a new therapeutic pathway. STC-15 aims to reprogram malignant cells. It modulates messenger RNA methylation. This process is vital for cell differentiation.
The company's lead candidate achieved a significant clinical milestone. STC-15 has entered Phase 2 clinical trials. The first patient has been dosed in this monotherapy study. The trial targets selected sarcoma indications. Sarcoma is a challenging cancer. It originates in bone or soft tissues. This includes muscle, fat, and cartilage. Sarcoma accounts for a small but significant percentage of cancers. It represents 1% of adult cancers. For children, it accounts for 15% of cancers.
Sarcomas often present unique treatment hurdles. They frequently lack clear driver mutations. They also possess few immunogenic features. Standard therapies struggle against these characteristics. This creates a substantial unmet medical need. Current options offer limited success. Sarcomas depend on METTL3-driven methylation. This process is critical for their growth and survival. STC-15 directly addresses this vulnerability. It aims to disrupt the cancer's fundamental machinery.
Previous Phase 1 monotherapy study results were promising. STC-15 demonstrated durable tumor regression. This occurred across multiple sarcoma subtypes. These findings underscore the drug's potential. It can target and reprogram progenitor cells. These cells transform into cancerous ones. The data supported advancing to Phase 2.
The Phase 2 study has clear objectives. It is designed to support a potential accelerated regulatory approval pathway. This would expedite patient access. The trial also establishes a foundation. It paves the way for subsequent clinical development. This includes exploration in additional oncology indications. The potential for broad application is significant.
STC-15's mechanism of action is groundbreaking. It inhibits METTL3. This enzyme regulates cancer stem cell differentiation. This process is critical in sarcoma development. It impacts other malignancies too. Reprogramming these cells can halt cancer progression. It can induce cell cycle arrest. It can also trigger apoptosis, or programmed cell death.
The funding round saw strong investor participation. Existing investors contributed to the Series C. These included M Ventures and Pfizer Ventures. Taiho Ventures LLC also participated. IP Group plc provided support. UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) joined in. Fast Track Initiative (FTI) completed the list. This investor confidence highlights the drug's potential. It validates STORM's scientific innovation.
STORM Therapeutics focuses on epitranscriptomic regulation. This field explores RNA modifications. It emphasizes their importance in stem cell-derived tumors. This research area holds immense promise. It reveals new targets for cancer intervention. STC-15 is the first RNA-modifying enzyme inhibitor. It has entered human clinical trials. This marks a pivotal moment in drug development.
The company's strategy is comprehensive. It addresses critical unmet needs. It seeks to develop new therapeutic options. These options benefit patients with aggressive cancers. The initial focus on sarcoma is strategic. It targets a high-need population. The broader implications for oncology are vast.
The successful dosing of the first patient signals progress. It represents a significant step. It brings a novel treatment closer to patients. The biotechnology industry watches these developments closely. New paradigms in cancer treatment are emerging. STC-15 could redefine sarcoma therapy. It offers a new weapon in the fight against cancer. This clinical advancement could save lives. It promises a brighter future for oncology.
STORM Therapeutics announced a major financial milestone. The company secured $56 million in Series C financing. This funding empowers critical clinical advancement. It targets a first-in-class cancer therapy. The focus is on STC-15, a novel drug candidate.
STC-15 is an oral, small-molecule inhibitor. It specifically targets METTL3. METTL3 is an RNA-modifying enzyme. This enzyme plays a crucial role in cancer development. Its inhibition offers a new therapeutic pathway. STC-15 aims to reprogram malignant cells. It modulates messenger RNA methylation. This process is vital for cell differentiation.
The company's lead candidate achieved a significant clinical milestone. STC-15 has entered Phase 2 clinical trials. The first patient has been dosed in this monotherapy study. The trial targets selected sarcoma indications. Sarcoma is a challenging cancer. It originates in bone or soft tissues. This includes muscle, fat, and cartilage. Sarcoma accounts for a small but significant percentage of cancers. It represents 1% of adult cancers. For children, it accounts for 15% of cancers.
Sarcomas often present unique treatment hurdles. They frequently lack clear driver mutations. They also possess few immunogenic features. Standard therapies struggle against these characteristics. This creates a substantial unmet medical need. Current options offer limited success. Sarcomas depend on METTL3-driven methylation. This process is critical for their growth and survival. STC-15 directly addresses this vulnerability. It aims to disrupt the cancer's fundamental machinery.
Previous Phase 1 monotherapy study results were promising. STC-15 demonstrated durable tumor regression. This occurred across multiple sarcoma subtypes. These findings underscore the drug's potential. It can target and reprogram progenitor cells. These cells transform into cancerous ones. The data supported advancing to Phase 2.
The Phase 2 study has clear objectives. It is designed to support a potential accelerated regulatory approval pathway. This would expedite patient access. The trial also establishes a foundation. It paves the way for subsequent clinical development. This includes exploration in additional oncology indications. The potential for broad application is significant.
STC-15's mechanism of action is groundbreaking. It inhibits METTL3. This enzyme regulates cancer stem cell differentiation. This process is critical in sarcoma development. It impacts other malignancies too. Reprogramming these cells can halt cancer progression. It can induce cell cycle arrest. It can also trigger apoptosis, or programmed cell death.
The funding round saw strong investor participation. Existing investors contributed to the Series C. These included M Ventures and Pfizer Ventures. Taiho Ventures LLC also participated. IP Group plc provided support. UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) joined in. Fast Track Initiative (FTI) completed the list. This investor confidence highlights the drug's potential. It validates STORM's scientific innovation.
STORM Therapeutics focuses on epitranscriptomic regulation. This field explores RNA modifications. It emphasizes their importance in stem cell-derived tumors. This research area holds immense promise. It reveals new targets for cancer intervention. STC-15 is the first RNA-modifying enzyme inhibitor. It has entered human clinical trials. This marks a pivotal moment in drug development.
The company's strategy is comprehensive. It addresses critical unmet needs. It seeks to develop new therapeutic options. These options benefit patients with aggressive cancers. The initial focus on sarcoma is strategic. It targets a high-need population. The broader implications for oncology are vast.
The successful dosing of the first patient signals progress. It represents a significant step. It brings a novel treatment closer to patients. The biotechnology industry watches these developments closely. New paradigms in cancer treatment are emerging. STC-15 could redefine sarcoma therapy. It offers a new weapon in the fight against cancer. This clinical advancement could save lives. It promises a brighter future for oncology.